Clinical Trial Update: Study of Camrelizumab in Combination With Apatinib Mesylate Plus Albumin-bound Paclitaxel and Cisplatin as the First Line Treatment of Recurrent or Metastatic, UnresectableHead and Neck Squamous Cell Carcinoma [Phase 2]

View source ↗

Summary

Phase 2 trial evaluating camrelizumab in combination with apatinib mesylate, albumin-bound paclitaxel, and cisplatin as first-line therapy for recurrent or meta…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Head and Neck Squamous Cell Carcinoma

Drugs mentioned

• Albumin-bound paclitaxel (nab-paclitaxel)
• Apatinib Mesylate (apatinib)
• CISPLATIN (cisplatin)
• Camrelizumab (camrelizumab)

Snippet

Sponsor: The First Affiliated Hospital of Zhengzhou University | Conditions: Head and Neck Squamous Cell Carcinoma | Phase 2 | Status: UNKNOWN